Testing QY201 tablets for non-segmental vitiligo
Part of Skin clinical trials.
This trial tests an experimental oral tablet called QY201 to see if it can improve vitiligo (white patches on the skin). It is for adults with non-segmental vitiligo, regardless of whether the patches are currently growing or stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You must have a doctor's diagnosis of non-segmental vitiligo (patches on both sides of the body).
- Your vitiligo must cover at least 5% of your body surface area.
- You must not have used certain strong medications or light therapy for vitiligo in the past few weeks.
- You must agree to use birth control during the study and for 3 months after the last dose.
- You cannot have had a skin graft or permanent depigmentation treatment for vitiligo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral tablet called SYHX1901 for people with non-segmental vitiligo. It aims to see if the pill is safe and effective at bringing back skin color.
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
This study tests whether a new tablet called LW402 can help restore skin color in people with non-segmental vitiligo (white patches that spread unpredictably across the body). The medication works by targeting immune cells that attack skin pigment.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
Hear when a new Adult Subjects With Non-Segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.